Cargando…
Improving outcomes in scleroderma: recent progress of cell-based therapies
Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of the disease, diffuse cutaneous scleroderma...
Autores principales: | Khanna, Dinesh, Krieger, Nancy, Sullivan, Keith M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234204/ https://www.ncbi.nlm.nih.gov/pubmed/36355455 http://dx.doi.org/10.1093/rheumatology/keac628 |
Ejemplares similares
-
Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020) -
Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations
por: Schwaiger, Johannes P., et al.
Publicado: (2013) -
Scleroderma with Nodular Scleroderma
por: Srisuttiyakorn, Chutika, et al.
Publicado: (2016) -
Update on mesenchymal stem cell-based therapy in lupus and scleroderma
por: Cras, Audrey, et al.
Publicado: (2015) -
Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma
por: Low, Andrea H. L., et al.
Publicado: (2019)